美国50-64岁成人重组带状疱疹疫苗(RZV)第二剂系列完成情况
研究利用两个行政数据库估计美国50-64岁成人中重组带状疱疹疫苗(RZV)第二剂系列完成率。结果显示,第二剂完成率在6个月内约70%,12个月内约80%;仅接种1剂且随访至少12个月者中,96%存在错失第二剂接种机会,其中36%在首剂后2-12个月内因流感或肺炎球菌疫苗接种就诊。
要点
- 50-64岁成人RZV第二剂完成率6个月内约70%,12个月内约80%。
- 仅接种1剂且随访≥12个月者中,96%存在错失第二剂接种机会。
- 错失机会者中36%在首剂后2-12个月内因流感或肺炎球菌疫苗接种就诊。
核心结论
- 50-64岁成人RZV系列完成率较高。
- 药房提供RZV可能有助于提高系列完成率,但错失机会仍然存在。
研究设计与样本
- 利用两个行政数据库估计美国50-64岁成人第二剂RZV系列完成率。
主要发现
- 第二剂RZV系列完成率在首剂后6个月内约70%,12个月内约80%。
- 仅接种1剂RZV且随访至少12个月者中,96%存在错失第二剂接种机会(定义为有提供者或药房就诊)。
- 错失机会者中36%在首剂RZV后2-12个月内因流感或肺炎球菌疫苗接种就诊。
关键数值与推荐
- 2018年CDC推荐50岁及以上免疫功能正常者接种2剂次RZV系列以预防带状疱疹,第二剂建议在第一剂后2-6个月接种。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2018, CDC recommended a highly efficacious adjuvanted recombinant zoster vaccine (RZV) as a 2-dose series for prevention of herpes zoster (HZ) for immunocompetent persons age ≥ 50 years, with the 2nd dose recommended 2-6 months after the 1st dose. We estimated second-dose RZV series completion in the U.S. among 50-64-year-olds using two administrative databases. Second-dose RZV series completion was ∼70% within 6-months and 80% within 12-months of first dose. Among those who received only 1 RZV dose with at least 12 months of follow-up time, 96% had a missed opportunity for a second-dose vaccination, defined as a provider or pharmacy visit, among whom 36% had a visit for influenza or pneumococcal vaccination within 2-12 months of their first-dose of RZV. We found that RZV series completion rates in 50-64-year-olds was high. Availability of RZV at pharmacies has potentially helped increase series completion, but missed opportunities remain.
引用
- Leung J, Gray EB, Anderson TC, et al. Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States. Vaccine. 2022. PMID: 36347721. doi:10.1016/j.vaccine.2022.10.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。